Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Cells. 2021 Mar 23;10(3):712. doi: 10.3390/cells10030712.
Despite advances in understanding of the molecular pathogenesis of glioma, outcomes remain dismal. Developing successful treatments for glioma requires faithful in vivo disease modeling and rigorous preclinical testing. Murine models, including xenograft, syngeneic, and genetically engineered models, are used to study glioma-genesis, identify methods of tumor progression, and test novel treatment strategies. Since the discovery of highly recurrent isocitrate dehydrogenase (IDH) mutations in lower-grade gliomas, there is increasing emphasis on effective modeling of IDH mutant brain tumors. Improvements in preclinical models that capture the phenotypic and molecular heterogeneity of gliomas are critical for the development of effective new therapies. Herein, we explore the current status, advancements, and challenges with contemporary murine glioma models.
尽管人们对神经胶质瘤的分子发病机制有了深入的了解,但结果仍然不容乐观。要开发出成功的神经胶质瘤治疗方法,需要进行忠实的体内疾病建模和严格的临床前测试。包括异种移植、同基因和基因工程模型在内的小鼠模型被用于研究神经胶质瘤发生、确定肿瘤进展的方法,并测试新的治疗策略。自从在低级别神经胶质瘤中发现高度复发的异柠檬酸脱氢酶 (IDH) 突变以来,人们越来越重视对 IDH 突变脑肿瘤进行有效的建模。改进能够捕捉神经胶质瘤表型和分子异质性的临床前模型对于开发有效的新疗法至关重要。本文探讨了当前小鼠神经胶质瘤模型的现状、进展和挑战。